FcRn拮抗剂治疗成人全身型重症肌无力临床应用的专家建议(2024)  

Expert Recommendations for the Clinical Application of FcRn Antagonists in the Treatment of Adult Generalized Myasthenia Gravis(2024)

作　　者：李志军 罗苏珊 岳耀先 周昊[4,13] 常婷 笪宇威 段瑞生[7,13] 王玉鸽 杨春生 杨欢[4,13] 张华 赵重波[2,13] 周红雨 冯慧宇[12,13] 卜碧涛 LI Zhi-jun;LUO Su-shan;YUE Yao-xian;ZHOU Hao;CHANG Ting;DA Yu-wei;DUAN Rui-sheng;WANG Yu-ge;YANG Chun-sheng;YANG Huan;ZHANG Hua;ZHAO Chong-bo;ZHOU Hong-yu;FENG Hui-yu;BU Bi-tao(Department of Neurology,Tongji Hospital Affiliated to Tongji Medical College,Huazhong University of Science&Technology,Wuhan 430030,China;Department of Neurology,Huashan Hospital Afiliated to Fudan University,National Center for Neurological Diseases(NCND),Shanghai 200040,China;Department of Neurology,Qilu Hospital,Shandong University,Qingdao 266035,China;Department of Neurology,Xiangya Hospital,Central South University,Changsha 410008,China;Department of Neurology,Tangdu Hospital of Air Force Medical University,Xi'an 710038,China;Department of Neurology,Xuanwu Hospital,Capital Medical University,National Center for Neurological Diseases(NCND),Beijing 100053,China;Department of Neurology,the First Afiliated Hospital of Shandong First Medical University,Jinan 250014,China;Department of Neurology,the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510635,China;Department of Neurology,Tianjin Medical University,General Hospital,Tianjin 300052,China;Department of Neurology,Beijing Hospital,Beijing 100730,China;Department of Neurology,West China Hospital of Sichuan University,Chengdu 610041,China;Department of Neurology,the First Affiliated Hospital of Sun Yat-Sen University,Guangzhou 510080,China;Chinese Myasthenia Gravis Collaborative Group(CMGCG),Beijing 100022,China)

机构地区：[1]华中科技大学同济医学院附属同济医院神经内科,武汉430030 [2]复旦大学附属华山医院神经内科,国家神经疾病医学中心,上海200040 [3]山东大学齐鲁医院(青岛)神经内科,青岛266035 [4]中南大学湘雅医院神经内科,长沙410008 [5]空军军医大学唐都医院神经内科,西安710038 [6]首都医科大学宣武医院神经内科,国家神经疾病医学中心,北京100053 [7]山东第一医科大学第一附属医院神经内科,济南250014 [8]中山大学附属第三医院神经内科,广州510635 [9]天津医科大学总医院神经内科,天津300052 [10]北京医院神经内科,北京100730 [11]四川大学华西医院神经内科,成都610041 [12]中山大学附属第一医院神经内科,广州510080 [13]中国罕见病联盟/北京罕见病诊疗与保障学会重症肌无力协作组,北京100022

出　　处：《中国临床神经科学》2025年第1期1-9,共9页Chinese Journal of Clinical Neurosciences

摘　　要：重症肌无力(MG)是一种由致病性自身抗体介导的神经-肌肉接头疾病。免疫治疗已成为MG的重要治疗方法,其中新生儿Fc受体(FcRn)拮抗剂作为一种全新靶向免疫治疗药物,通过与免疫球蛋白(IgG)竞争性结合FcRn而加速清除致病性IgG,在临床实践中治疗乙酰胆碱受体抗体(AChR-ab)阳性成人全身型重症肌无力(gMG)显示出良好的疗效和安全性。鉴于上市之初临床医生用药经验尚不丰富,为进一步指导临床合理、有效、安全应用FcRn拮抗剂,中国罕见病联盟/北京罕见病诊疗与保障学会重症肌无力协作组牵头制定了FcRn拮抗剂治疗成人gMG临床应用的专家建议,旨在为中国临床医生提供用药参考。Aim Myasthenia gravis(MG)is a neuromuscular junction disease that is mediated by pathological autoantibodies against acetylcholine receptor,muscle-specific receptor tyrosine kinase or low-density lipoprotein receptor-related protein 4-antibody.Immunotherapy has become an important treatment for MG.As a novel type of targeted immunotherapy drug for MG,neonatal Fc receptor(FcRn)antagonists bind to FcRn and inhibit its interaction with IgG,thereby increase degradation of immunoglobulin(IgG)and autoantibodies.FcRn antagonists have excellent efficacy and safety in the treatment of acetylcholine receptor antibody positive adult generalized myasthenia gravis(gMG)in clinical practice.In view of the limited medication experience of clinicians at the beginning of marketing in China,the expert recommendations for the clinical application of FcRn antagonists in the treatment of adult gMG were formulated by the Myasthenia Gravis Collaboration Group of the China Rare Disease Alliance/Beijing Rare Disease Diagnosis,Treatment and Protection Society to provide medication references for Chinese clinicians on the rational,effective and safe application of FcRn antagonists.

关 键 词：新生儿Fc受体 FcRn拮抗剂 全身型重症肌无力 治疗 专家建议 

分 类 号：R746.1[医药卫生—神经病学与精神病学]